- Home
- IGC vs GDTC Comparison
IGC vs GDTC Comparison
Compare IGC & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGC
- GDTC
- Stock Information
- Founded
- IGC 2005
- GDTC 2018
- Country
- IGC United States
- GDTC Singapore
- Employees
- IGC N/A
- GDTC 34
- Industry
- IGC Biotechnology: Pharmaceutical Preparations
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- IGC Health Care
- GDTC Health Care
- Exchange
- IGC Nasdaq
- GDTC Nasdaq
- Market Cap
- IGC 26.9M
- GDTC 25.7M
- IPO Year
- IGC N/A
- GDTC 2023
- Fundamental
- Price
- IGC $0.35
- GDTC $2.20
- Analyst Decision
- IGC Strong Buy
- GDTC Buy
- Analyst Count
- IGC 2
- GDTC 1
- Target Price
- IGC $3.63
- GDTC $5.00
- AVG Volume (30 Days)
- IGC 222.5K
- GDTC 13.3K
- Earning Date
- IGC 11-12-2024
- GDTC 01-01-0001
- Dividend Yield
- IGC N/A
- GDTC N/A
- EPS Growth
- IGC N/A
- GDTC N/A
- EPS
- IGC N/A
- GDTC N/A
- Revenue
- IGC $1,183,000.00
- GDTC $330,254.00
- Revenue This Year
- IGC N/A
- GDTC $14.71
- Revenue Next Year
- IGC $13.57
- GDTC N/A
- P/E Ratio
- IGC N/A
- GDTC N/A
- Revenue Growth
- IGC N/A
- GDTC N/A
- 52 Week Low
- IGC $0.25
- GDTC $1.20
- 52 Week High
- IGC $0.91
- GDTC $5.50
- Technical
- Relative Strength Index (RSI)
- IGC 42.76
- GDTC 49.23
- Support Level
- IGC $0.33
- GDTC $1.88
- Resistance Level
- IGC $0.42
- GDTC $2.35
- Average True Range (ATR)
- IGC 0.02
- GDTC 0.36
- MACD
- IGC -0.00
- GDTC -0.05
- Stochastic Oscillator
- IGC 32.14
- GDTC 37.00
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.